Iovance Biotherapeutics, Inc. (2LB.F)
- Previous Close
11.26 - Open
10.99 - Bid 10.65 x 100000
- Ask 10.73 x 100000
- Day's Range
10.99 - 10.99 - 52 Week Range
3.11 - 16.85 - Volume
37 - Avg. Volume
1,094 - Market Cap (intraday)
3.07B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-1.77 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.31
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
www.iovance.comRecent News: 2LB.F
Performance Overview: 2LB.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2LB.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2LB.F
Valuation Measures
Market Cap
3.06B
Enterprise Value
2.87B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.38k
Price/Book (mrq)
5.76
Enterprise Value/Revenue
2.41k
Enterprise Value/EBITDA
-6.70
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.86%
Return on Equity (ttm)
-81.91%
Revenue (ttm)
1.19M
Net Income Avi to Common (ttm)
-444.04M
Diluted EPS (ttm)
-1.77
Balance Sheet and Cash Flow
Total Cash (mrq)
279.87M
Total Debt/Equity (mrq)
12.98%
Levered Free Cash Flow (ttm)
-211.47M
Research Analysis: 2LB.F
Company Insights: 2LB.F
2LB.F does not have Company Insights